GlassScriptPhysician profile
Steven J Hager
NPI 1326087917
$102,472.67
in general payments reported to CMS, 2019-2025
71 companies · $14K in 2025
The $14K reported for 2025 was more than what 91% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $8,215 · 2020: $15K · 2021: $21K · 2022: $7,949 · 2023: $29K · 2024: $8,290 · 2025: $14K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $39K · Food and Beverage: $5,230 · Travel and Lodging: $4,449 · Honoraria: $2,520 · Education: $102 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $42.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $38,680.25 |
| Food and Beverage | $5,229.75 |
| Travel and Lodging | $4,448.84 |
| Honoraria | $2,520.00 |
| Education | $101.75 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $42.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $16,853.18 | 2019-2025 | Lynparza, Imfinzi, Calquence |
| Daiichi Sankyo INC. | $16,474.64 | 2020-2024 | Enhertu, Injectafer, Vanflyta |
| Seagen INC. | $8,844.29 | 2019-2023 | Adcetris, Padcev |
| Stemline Therapeutics INC. | $8,507.78 | 2023-2025 | Orserdu |
| Cornerstone Specialty Network LLC | $8,180.12 | 2019-2021 | |
| Epizyme, INC. | $7,344.56 | 2020-2021 | |
| E.R. Squibb & Sons, L.L.C. | $6,785.42 | 2019-2025 | Opdivo, Reblozyl, Opdualag |
| Karyopharm Therapeutics INC. | $3,874.19 | 2020-2022 | |
| Shield Therapeutics INC | $3,201.35 | 2023 | Accrufer |
| Celgene Corporation | $2,553.65 | 2020-2025 | Opdualag, Pomalyst, Reblozyl |
| Array Biopharma INC | $2,441.71 | 2021-2025 | Lorbrena, Braftovi, Mektovi |
| Amgen INC. | $2,312.59 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $2,257.36 | 2021-2025 | Fruzaqla, Ninlaro |
| Glaxosmithkline, LLC. | $1,934.26 | 2019-2025 | Zejula, Jemperli, Ojjaara |
| Pfizer INC. | $1,770.19 | 2019-2025 |
Show all 66 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Morphosys, US INC. | $1,456.90 | 2021 | |
| Exelixis INC. | $1,431.14 | 2019-2025 | Cabometyx |
| Novartis Pharmaceuticals Corporation | $570.81 | 2019-2025 | |
| Alexion Pharmaceuticals, INC. | $491.65 | 2019-2023 | Ultomiris |
| Incyte Corporation | $378.03 | 2020-2025 | Jakafi, Niktimvo, Monjuvi |
| Abbvie INC. | $338.91 | 2019-2025 | |
| Lilly USA, LLC | $315.64 | 2019-2025 | Jaypirca, Verzenio, Retevmo |
| Novocure Gmbh | $250.00 | 2022 | |
| Genentech USA, INC. | $234.69 | 2019-2023 | Tecentriq |
| Kite Pharma, INC. | $230.66 | 2019-2023 | Yescarta |
| Pharmacyclics LLC, An Abbvie Company | $214.80 | 2019-2023 | Epkinly, Imbruvica |
| Ipsen Biopharmaceuticals, INC | $209.68 | 2021-2025 | Onivyde, Tazverik |
| Sirtex Medical INC | $192.40 | 2019-2024 | Sir-Spheres Microspheres |
| Merck Sharp & Dohme LLC | $189.05 | 2019-2025 | Keytruda, Welireg, Keytruda Qlex |
| Octapharma USA, INC. | $178.41 | 2019 | |
| Athenex Pharmaceutical Division, LLC | $175.00 | 2020 | |
| Regeneron Healthcare Solutions, INC. | $166.90 | 2021-2023 | Libtayo |
| Genzyme Corporation | $165.70 | 2019-2025 | |
| Agios Pharmaceuticals, INC. | $165.46 | 2024-2025 | Pyrukynd |
| Sobi, INC | $163.24 | 2022-2025 | |
| Springworks Therapeutics, INC. | $161.84 | 2024-2025 | Ogsiveo |
| Cardinal Health 108 LLC | $152.50 | 2019 | |
| Gilead Sciences, INC. | $121.41 | 2019-2024 | Trodelvy |
| Beigene USA, INC. | $102.36 | 2021-2024 | Brukinsa |
| Comsort, INC | $100.00 | 2019 | |
| Pharmaessentia USA Corporation | $96.78 | 2023-2025 | Besremi |
| Spectrum Pharmaceuticals INC. | $94.82 | 2019 | |
| Janssen Biotech, INC. | $89.64 | 2019-2024 | Carvykti, Rybrevant |
| Eisai INC. | $65.43 | 2019-2024 | |
| Coherus Oncology, INC. | $62.11 | 2020-2021 | |
| Myovant Sciences INC. | $58.95 | 2021-2022 | |
| Emd Serono, INC. | $52.56 | 2021-2022 | |
| Tersera Therapeutics LLC | $41.54 | 2019 | |
| Deciphera Pharmaceuticals INC. | $37.15 | 2021-2025 | Romvimza, Qinlock |
| Novocure INC. | $36.31 | 2025 | Optune Lua (Novottf-200t) |
| Astellas Pharma US INC | $34.65 | 2019-2024 | Padcev |
| Bayer Healthcare Pharmaceuticals INC. | $33.15 | 2019 | |
| Pharmacosmos Therapeutics INC. | $29.51 | 2024 | Monoferric |
| Boehringer Ingelheim Pharmaceuticals, INC. | $29.42 | 2024-2025 | Gilotrif |
| Tempus Ai, INC | $28.16 | 2025 | Xt Cdx |
| Immunogen, INC. | $23.58 | 2023 | Elahere |
| Taiho Oncology, INC. | $22.78 | 2024 | |
| Cumberland Pharmaceuticals, INC. | $20.96 | 2025 | Sancuso |
| Genmab U.S., INC. | $18.51 | 2023 | Epkinly |
| Dova Pharmaceuticals | $18.48 | 2021 | |
| Acrotech Biopharma INC. | $15.88 | 2021 | |
| Puma Biotechnology, INC. | $15.02 | 2021 | |
| Myriad Genetic Laboratories, INC. | $14.45 | 2022 | |
| Beone Medicines USA, INC. | $14.34 | 2025 | Brukinsa |
| Servier Pharmaceuticals LLC | $14.05 | 2024 | |
| Tesaro, INC. | $11.97 | 2019 |
5 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$11,279.61 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
$4,800.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Hager listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.